SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis
USA - NASDAQ:SNOA - US83558L3033 - Common Stock
3.94 USD
-0.01 (-0.25%)
Taking everything into account, SNOA scores 2 out of 10 in our fundamental rating. SNOA was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SNOA have multiple concerns. While showing a medium growth rate, SNOA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SNOA has reported negative net income.
SNOA had a negative operating cash flow in the past year.
In the past 5 years SNOA always reported negative net income.
SNOA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SNOA has a Return On Assets (-24.36%) which is in line with its industry peers.
SNOA has a Return On Equity of -87.65%. This is comparable to the rest of the industry: SNOA outperforms 44.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.36% | ||
| ROE | -87.65% | ||
| ROIC | N/A |
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNOA has a better Gross Margin (37.71%) than 60.94% of its industry peers.
In the last couple of years the Gross Margin of SNOA has declined.
SNOA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNOA has been increased compared to 1 year ago.
Compared to 5 years ago, SNOA has less shares outstanding
The debt/assets ratio for SNOA has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -17.84, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SNOA (-17.84) is worse than 81.25% of its industry peers.
SNOA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
SNOA has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: SNOA outperforms 53.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.84 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
SNOA has a Current Ratio of 2.70. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
SNOA has a Current ratio (2.70) which is in line with its industry peers.
A Quick Ratio of 1.92 indicates that SNOA should not have too much problems paying its short term obligations.
The Quick ratio of SNOA (1.92) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.64% over the past year.
Looking at the last year, SNOA shows a quite strong growth in Revenue. The Revenue has grown by 17.44% in the last year.
The Revenue has been decreasing by -4.44% on average over the past years.
EPS 1Y (TTM)46.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%18.4%
3.2 Future
SNOA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.06% yearly.
The Revenue is expected to grow by 17.80% on average over the next years. This is quite good.
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNOA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNOA's earnings are expected to grow with 15.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.06%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SNOA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SNOA (10/31/2025, 8:14:17 PM)
3.94
-0.01 (-0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.31%
Inst Owner Change0.45%
Ins Owners1.28%
Ins Owner Change0%
Market Cap6.50M
Revenue(TTM)14.91M
Net Income(TTM)-3555000
Analysts85.71
Price Target15.1 (283.25%)
Short Float %2.81%
Short Ratio0.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-17.11%
Max Revenue beat(2)-2.81%
Revenue beat(4)0
Avg Revenue beat(4)-11.43%
Min Revenue beat(4)-17.11%
Max Revenue beat(4)-2.81%
Revenue beat(8)0
Avg Revenue beat(8)-14.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.6 | ||
| P/tB | 1.6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.46
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS9.04
BVpS2.46
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.36% | ||
| ROE | -87.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.71% | ||
| FCFM | N/A |
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
F-Score4
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 134.07% | ||
| Cap/Sales | 1.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z | -17.84 |
F-Score4
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)91.77%
Cap/Depr(5y)85.45%
Cap/Sales(3y)0.91%
Cap/Sales(5y)0.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.44%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%18.4%
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.39%
OCF growth 3YN/A
OCF growth 5YN/A
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What is the ChartMill fundamental rating of SONOMA PHARMACEUTICALS INC (SNOA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to SNOA.
What is the valuation status for SNOA stock?
ChartMill assigns a valuation rating of 0 / 10 to SONOMA PHARMACEUTICALS INC (SNOA). This can be considered as Overvalued.
Can you provide the profitability details for SONOMA PHARMACEUTICALS INC?
SONOMA PHARMACEUTICALS INC (SNOA) has a profitability rating of 1 / 10.